YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites

Stock News

May 07

YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1181865718"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181865718\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181865718?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181865718","market":"sg","top_or_hot":-1,"title":"YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites","media":"Stock News","content":"<p>YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-07 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1181865718","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181865718","pubTimestamp":1778146700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","IPOS":"Renaissance International IPO ETF","02496":"友芝友生物-B"},"translate_title":"友济生物-B获NMPA受理M701靶向恶性腹水新药申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02496":1,"IPOS":1},"content_text":"YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}